Mark E. Dmytruk - 03 Mar 2025 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role
Chief Financial Officer
Signature
/s/ Karen Tepichin, Attorney-in-Fact
Issuer symbol
DNA
Transactions as of
03 Mar 2025
Net transactions value
-$6,103
Form type
4
Filing time
06 Mar 2025, 17:00:57 UTC
Previous filing
06 Feb 2025
Next filing
10 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNA Class A Common Stock Options Exercise +454 +1.3% 34,417 03 Mar 2025 Direct F1
transaction DNA Class A Common Stock Options Exercise +453 +1.3% 34,870 03 Mar 2025 Direct F1
transaction DNA Class A Common Stock Options Exercise +572 +1.6% 35,442 03 Mar 2025 Direct F1
transaction DNA Class A Common Stock Sale $6,103 -790 -2.2% $7.72 34,652 04 Mar 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNA Restricted Stock Units Options Exercise -454 -9.1% 4,522 03 Mar 2025 Class A Common Stock 454 Direct F1
transaction DNA Restricted Stock Units Options Exercise -453 -4% 10,876 03 Mar 2025 Class A Common Stock 453 Direct F1, F3
transaction DNA Restricted Stock Units Options Exercise -572 -2.7% 20,632 03 Mar 2025 Class A Common Stock 572 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2 Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock and/or restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.
F3 The RSUs vest in 48 equal monthly installments, which began on April 1, 2023.
F4 The RSUs vest in 48 equal monthly installments, which began on April 1, 2024.

Remarks:

Chief Financial Officer